SCHEMBL501876

SCHEMBL501876

O=CNc1ccccc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
KMT2A Q03164 5/20 0.57
KDM4E B2RXH2 4/20 0.57
MAPT P10636 3/20 0.57
MEN1 O00255 3/20 0.57
POLB P06746 1/20 0.57
PKM P14618 2/20 0.54
FABP4 P15090 2/20 0.53
HPGD P15428 3/20 0.53
HSD17B10 Q99714 2/20 0.53
ALOX15 P16050 1/20 0.52
RAB9A P51151 2/20 0.50
FABP3 P05413 1/20 0.50
FABP5 Q01469 1/20 0.50
NPC1 O15118 1/20 0.50
TP53 P04637 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
AGTR1 P30556 1/20 0.49
DHODH Q02127 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29413047 1.00 ALDH1A1 (0.57) ALDH1A1KMT2AKDM4EMAPTMEN1
SCHEMBL14390473 0.82 KMT2A (0.56) ALDH1A1KMT2AKDM4EMAPTPOLB
SCHEMBL4297093 0.82 ALDH1A1 (0.51) ALDH1A1KMT2AKDM4EMAPTMEN1
SCHEMBL5543487 0.82 PBRM1 (0.46) ALDH1A1KMT2AKDM4EMAPTMEN1
SCHEMBL3900033 0.82 RXFP1 (0.49) ALDH1A1KMT2AKDM4EMAPTMEN1
SCHEMBL9163256 0.82 RXFP1 (0.46) ALDH1A1KMT2AKDM4EMAPTMEN1
SCHEMBL4206945 0.82 ALDH1A1 (0.56) ALDH1A1KMT2AKDM4EMAPTMEN1
SCHEMBL2612359 0.82 KDM4E (0.58) ALDH1A1KMT2AKDM4EMAPTMEN1
SCHEMBL29467931 0.82 RXFP1 (0.49) ALDH1A1KMT2AKDM4EMAPTMEN1
SCHEMBL11656158 0.82 ALDH1A1 (0.56) ALDH1A1KMT2AKDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease SOCIETE DES PRODUITS NESTLE S.A. (CH) 2026-03-24 US claimed
WO-2024190663-A1 BIOMARKER AND USE THEREOF 株式会社明治 2024-09-19 WO claimed
CN-116814119-A Bottom anti-reflective coating composition and pattern forming method 长鑫存储技术有限公司 2023-09-29 CN claimed
US-20230204604-A1 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE SOCIETE DES PRODUITS NESTLE S.A. (CH) 2023-06-29 US claimed
CN-114558061-B Loquat leaf extract and preparation method and application thereof 浙江大学 2023-04-04 CN claimed
CN-115915796-A Multifunctional Lewis base molecule modified high-stability perovskite solar cell 河北工业大学 2023-04-04 CN claimed
US-20220208386-A1 DIAGNOSTIC FOR MATERNAL RISK OF HAVING A CHILD WITH AUTISM SPECTRUM DISORDER ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2022-06-30 US claimed
CN-114558061-A Loquat leaf extract and preparation method and application thereof 浙江大学 2022-05-31 CN claimed
EP-3947732-A2 DIAGNOSTIC FOR MATERNAL RISK OF HAVING A CHILD WITH AUTISM SPECTRUM DISORDER Arizona Board of Regents on behalf of Arizona State University (US) 2022-02-09 EP claimed
CN-112292035-A Water-dispersible pesticide composition 日本化药株式会社 2021-01-29 CN claimed
EP-0813510-A4 METHODS AND COMPOSITIONS FOR ENHANCING FORMYLTETRAHYDROPTEROYLPOLYGLUTAMATE IN PLANTS NONOMURA ARTHUR M (US) 2000-07-26 EP claimed
EP-0589665-B1 4,5,6,7-Tetrahydro-1H-imidazo 4,5-c pyridine-6-carboxylic acid amide derivatives as angiotensine II antagonistes KUREHA CHEMICAL IND CO LTD (JP) 1999-11-17 EP claimed
EP-0950655-A1 AMINOMETHYLENE DERIVATIVES AND ULTRAVIOLET ABSORBER COMPRISING THE SAME CHEMIPRO KASEI KAISHA, LIMITED (JP) 1999-10-20 EP claimed
EP-0813510-A1 METHODS AND COMPOSITIONS FOR ENHANCING FORMYLTETRAHYDROPTEROYLPOLYGLUTAMATE IN PLANTS NONOMURA, Arthur M. (US) 1997-12-29 EP claimed
WO-1996027572-A1 METHODS AND COMPOSITIONS FOR ENHANCING FORMYLTETRAHYDROPTEROYLPOLYGLUTAMATE IN PLANTS NONOMURA ARTHUR M (US) 1996-09-12 WO claimed
US-5401736-A Angiotensis II antagonists KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1995-03-28 US claimed
EP-0372486-B1 Benzoic-acid phenylacetic-acid derivatives, their preparation and their use as medicines HOFFMANN LA ROCHE (CH) 1994-06-01 EP claimed
EP-0589665-A2 4,5,6,7-Tetrahydro-1H-imidazo 4,5-c pyridine-6-carboxylic acid amide derivatives as angiotensine II antagonistes KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1994-03-30 EP claimed
EP-0372486-A2 Benzoic-acid phenylacetic-acid derivatives, their preparation and their use as medicines F. HOFFMANN-LA ROCHE AG (CH) 1990-06-13 EP claimed
US-4002665-A Process for substituted cyclohexenes and its products WARNER-LAMBERT COMPANY (US) 1977-01-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease GLS, AADAT, FGF23 ALDH1A1 822/4885KMT2A 119/4885KDM4E 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.